Ignacio Garrido-Laguna, MD
Medical Oncology · Salt Lake City, UTNPI 1467608554
Payments from drug & device makers
Across 1,028 payments — averaging $8596.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.9M
- Novartis$1.4M
- Pfizer$1.1M
- Array Biopharma Inc$583K
- GSK$562K
- AstraZeneca$403K
- plus $2.9M from 19 others
Across 16 payments — averaging $1346.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$13K
- Eli Lilly$7K
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$19,11055%
- Speaking & faculty fees$9,28627%
- Travel & lodging$5,52216%
- Food & beverage$7972%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $1,934,085 |
| Novartis | 9 | $1,387,461 |
| Pfizer | 69 | $1,082,777 |
| Array Biopharma Inc | 11 | $583,460 |
| GSK | 16 | $561,866 |
| AstraZeneca | 9 | $402,762 |
| Bayer | 107 | $387,241 |
| Daiichi Sankyo Inc. | 318 | $365,414 |
| Incyte Corporation | 119 | $359,744 |
| Eli Lilly | 17 | $314,520 |
| Seagen Inc. | 27 | $239,092 |
| E.r. Squibb & Sons, L.L.C. | 8 | $189,107 |
| Genentech, Inc. | 98 | $188,451 |
| Sumitomo Pharma America, Inc. | 19 | $188,210 |
| Taiho Oncology, Inc. | 24 | $187,722 |
| Halozyme Inc | 80 | $175,305 |
| Astrazeneca UK Limited | 4 | $87,869 |
| Verastem, Inc. | 1 | $74,165 |
| Agios Pharmaceuticals, Inc. | 19 | $53,298 |
| Redhill Biopharma Inc. | 25 | $36,872 |
| Merck | 3 | $16,200 |
| AbbVie | 7 | $9,687 |
| Eisai Inc. | 10 | $6,776 |
| Jazz Pharmaceuticals Inc. | 1 | $2,560 |
| F. Hoffmann-la Roche AG | 4 | $2,447 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$6,540
- MEKTOVI$4,200
- ZEPZELCA$2,560
- Non-Covered Product$2,447
How this compares
$8,837,090 in reported general payments places this provider in the 95th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Salt Lake City
- Wallace AkerleySalt Lake City$12.7M
- Stephan KendallSalt Lake City$10.2M
- William McKeanSalt Lake City$3.4M
- Bradley HunterSalt Lake City$3.3M
- Ahmad HalwaniSalt Lake City$2.3M
- Paul ShamiSalt Lake City$1.5M
- Kenneth GrossmannSalt Lake City$931K
- Martha GlennSalt Lake City$768K
- Jeff RussellSalt Lake City$739K
- Mei WeiSalt Lake City$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.